Company Overview of Apotex Inc.
Apotex Inc., a pharmaceutical company, engages in the research and development, manufacture, distribution, and sale of generic pharmaceuticals in Canada and internationally. It offers medicines in various dosage forms. The company serves patients, healthcare providers, payers, and governments. It offers its products through pharmacies and healthcare facilities. The company was founded in 1974 and is based in Toronto, Canada with additional offices in Saudi Arabia. It has facilities in Montreal, Richmond Hill, Toronto, Etobicoke, Mississauga, Brantford, Windsor, Winnipeg, London, Calgary, and Vancouver, Canada; and subsidiaries, joint ventures, and licensing agreements in Australia, Belgium, ...
150 Signet Drive
Toronto, ON M9L 1T9
Founded in 1974
Key Executives for Apotex Inc.
Founder and Chairman of the Board
President of Apotex International
Director of Research and Development
Director of Marketing -Canada
Compensation as of Fiscal Year 2013.
Apotex Inc. Key Developments
Ferring Pharmaceuticals Inc. Receives Positive Verdict in Patent Infringement Lawsuit for LYSTEDA(R) (tranexamic acid)
Feb 3 14
Ferring Pharmaceuticals Inc. announced that their patents for LYSTEDA(R) (tranexamic acid), a non-hormonal prescription medicine to treat heavy monthly menstrual bleeding, have been found valid and infringed by both Watson Pharmaceuticals Inc. (Watson) and Apotex Inc. The separate lawsuits against Watson and Apotex were filed by Ferring in July 2011 and alleged that the Abbreviated New Drug Applications (ANDAs) filed by each for tranexamic acid tablets, the generic equivalent to LYSTEDA, infringe Ferring's patents for the product. The positive verdicts by the court confirm LYSTEDA's exclusivity. Watson and Apotex can appeal the decisions and/or attempt to amend their respective ANDAs that exclude infringing products.
Apotex Inc. Open Three New Offices in Jeddah, Riyadh and Dammam, Saudi Arabia
Dec 12 13
Apotex Inc. has opened new offices in Jeddah, Riyadh and Dammam, Saudi Arabia. Currently, the three Apotex sites are operating with 41 new employees with plans to expand these numbers in the future.
AstraZeneca Receives $76 Million in Patent Dispute
Dec 3 13
AstraZeneca was awarded $76 million in damages in a court ruling related to a patent dispute. The U.S. District Court for the Southern District of New York found Apotex Corp.'s sales of generic omeprazole between 2004 and 2007 infringed on AstraZeneca's formulation patents for Prilosec. Prilosec is used to treat symptoms of gastroesophageal reflux disease, also known as GERD, and other conditions caused by excess stomach acid. The drug has lost its patent protection and is now sold over-the-counter.
Similar Private Companies By Industry
Recent Private Companies Transactions